Processa Pharmaceuticals, Inc. Amortization of Debt Issuance Costs and Discounts
Processa Pharmaceuticals, Inc. (PCSA) reported Amortization of Debt Issuance Costs and Discounts of $115.61 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-29.
Discontinued › Cash Flow › Operating Activities
us-gaap:AmortizationOfFinancingCostsAndDiscounts · last filed 2024-03-29
- Processa Pharmaceuticals, Inc. amortization of debt issuance costs and discounts for the quarter ending 2022-12-31 was $37.50K.
- Processa Pharmaceuticals, Inc. amortization of debt issuance costs and discounts for the quarter ending 2022-09-30 was $37.50K.
- Processa Pharmaceuticals, Inc. amortization of debt issuance costs and discounts for the quarter ending 2022-06-30 was $37.50K.
- Processa Pharmaceuticals, Inc. amortization of debt issuance costs and discounts for the quarter ending 2022-03-31 was $3.11K.
- Processa Pharmaceuticals, Inc. amortization of debt issuance costs and discounts for fiscal 2022 was $115.61K.
- Processa Pharmaceuticals, Inc. amortization of debt issuance costs and discounts for fiscal 2020 was $199.90K, a 11111.44% increase from fiscal 2019.
- Processa Pharmaceuticals, Inc. amortization of debt issuance costs and discounts for fiscal 2019 was $1.78K, a 97.34% decline from fiscal 2018.
- Processa Pharmaceuticals, Inc. amortization of debt issuance costs and discounts for fiscal 2018 was $67.07K, a 186.99% increase from fiscal 2017.
| Period end | Amortization of Debt Issuance Costs and Discounts 3 month | Amortization of Debt Issuance Costs and Discounts 6 month | Amortization of Debt Issuance Costs and Discounts 9 month | Amortization of Debt Issuance Costs and Discounts 12 month |
|---|---|---|---|---|
| 2022-12-31 | $37.50K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $75.00K derived: sum of 2 quarters · filed 2024-03-29 | $112.50K derived: sum of 3 quarters · filed 2024-03-29 | $115.61K 10-K · filed 2024-03-29 |
| 2022-09-30 | $37.50K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $75.00K derived: sum of 2 quarters · filed 2023-11-13 | $78.11K 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $37.50K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $40.61K 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $3.11K 10-Q · filed 2023-05-15 | |||
| 2020-12-31 | $42.77K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $197.76K derived: sum of 2 quarters · filed 2022-03-30 | $198.83K derived: sum of 3 quarters · filed 2022-03-30 | $199.90K 10-K · filed 2022-03-30 |
| 2020-09-30 | $154.99K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $156.06K derived: sum of 2 quarters · filed 2021-11-12 | $157.13K 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $1.07K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $2.14K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $1.07K 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | $1.78K 10-K · filed 2021-03-25 | |||
| 2018-12-31 | $2.23K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-06 | $5.94K derived: sum of 2 quarters · filed 2020-03-06 | $30.93K derived: sum of 3 quarters · filed 2020-03-06 | $67.07K 10-K · filed 2020-03-06 |
| 2018-09-30 | $3.71K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $28.70K derived: sum of 2 quarters · filed 2019-11-14 | $64.84K 10-Q · filed 2019-11-14 | |
| 2018-06-30 | $24.99K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $61.13K 10-Q · filed 2019-08-14 | ||
| 2018-03-31 | $36.14K 10-Q · filed 2019-05-14 | |||
| 2017-12-31 | $23.37K 10-K/A · filed 2019-04-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |